Adial Pharmaceuticals announced on December 3, 2024, that the United States Patent and Trademark Office (USPTO) issued patent number 12150931 on November 26, 2024. This patent expands the company’s intellectual property coverage for its lead investigational drug, AD04.
The patent covers a broader range of genotype combinations identified by Adial’s proprietary genetic diagnostic for the targeted treatment of alcohol use disorder (AUD). These combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are integral to the company's precision medicine approach.
This granted patent is a key part of Adial's strategy to protect AD04 for AUD treatment by patenting all possible genotype combinations identified in its clinical program. The patent strengthens IP protection through 2031, aiming for the broadest possible coverage for its genetically targeted asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.